TH-138: Phase II Randomized Trial of Carboplatin = Pemetrexed + Bevaciumab, with or without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or have never Smoked
This study is currently enrolling.
The purpose of this research study is to determine if the combination therapy of carboplatin, pemetrexed, bevacizumab (Avastin) and atezolizumab (Tecentriq) is better at controlling disease progression in never smoker and sensi ...